You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

First Relapse

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Selinexor, Daratumumab and Dexamethasone in Chinese Multiple

Not yet recruiting
  • Multiple Myeloma at First Relapse
    • (no location specified)
    Sep 27, 2022

    ACUTE LYMPHOBLASTIC LEUKEMIA Trial (Inotuzumab ozogamicin, ALLR3)

    Not yet recruiting
    • ACUTE LYMPHOBLASTIC LEUKEMIA
    • (no location specified)
    Feb 17, 2023

    Multiple Myeloma Trial in Cologne (Daratumumab)

    Recruiting
    • Multiple Myeloma
    • Cologne, Germany
      University of Cologne
    Apr 4, 2022

    Glioma of Brain Trial in Bern, Lausanne, Zürich (L19TNF)

    Active, not recruiting
    • Glioma of Brain
    • Bern, Switzerland
    • +2 more
    Apr 7, 2022

    Multiple Myeloma at First Relapse Trial in France (Ixazomib, Iberdomide, Dexamethasone Oral)

    Recruiting
    • Multiple Myeloma at First Relapse
    • Annecy, France
    • +20 more
    Dec 16, 2021

    Digital Droplet PCR in Early Period After Allo-HSCT to Predict

    Completed
    • Measurable Residual Disease
    • Digital Droplet PCR
    • Hangzhou, Zhejiang, China
      The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
    Aug 17, 2023

    Acute Myeloid Leukemia Trial in Hefei (RC1012 injection (allo-DNT cells))

    Recruiting
    • Acute Myeloid Leukemia
    • RC1012 injection (allo-DNT cells)
    • Hefei, Anhui, China
      The First Hospital of the University of Science and Technology o
    May 17, 2023

    Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)

    Terminated
    • Neuroblastoma Recurrent
    • Naxitamab and GM-CSF in combination with irinotecan and temozolomide
    • Hong Kong, Hong Kong
    • +2 more
    Nov 8, 2022

    Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • Changchun, China
    • +5 more
    Jan 27, 2023

    Multiple Myeloma, First Relapse Trial in France (PCD, Autologous transplantation (ASCT))

    Active, not recruiting
    • Multiple Myeloma
    • First Relapse
    • PCD
    • Autologous transplantation (ASCT)
    • Amiens, France
    • +29 more
    Jul 13, 2022

    Immune Thrombocytopenia Trial in Beijing (Baricitinib 2 MG [Olumiant], Danazol)

    Not yet recruiting
    • Immune Thrombocytopenia
    • Beijing, Beijing, China
    • +9 more
    May 2, 2023

    Anorexia Nervosa Trial in France (Eatline, Control)

    Recruiting
    • Anorexia Nervosa
    • Eatline
    • Control
    • Hénin-Beaumont, France
    • +5 more
    Feb 28, 2022

    ITP, Immune Thrombocytopenia Trial in Beijing (Iguratimod, Danazol)

    Recruiting
    • ITP
    • Immune Thrombocytopenia
    • Beijing, China
    • +1 more
    Apr 29, 2022

    B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

    Active, not recruiting
    • B-cell Lymphoma
    • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of Med
    Sep 28, 2022

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (BCMA CAR-NK, Cyclophosphamide, Fludarabine

    Recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • BCMA CAR-NK
    • +2 more
    • Hangzhou, Zhejiang, China
    • +1 more
    Feb 17, 2023

    Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Umbilical Cord Blood

    Recruiting
    • Hematopoietic Malignancy
    • +2 more
    • Umbilical Cord Blood Transplantation
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow university
    Nov 6, 2023

    Epithelial Ovarian Cancer Trial in Chula Vista, San Antonio, Heidelberg (MORAb-003)

    Terminated
    Has Results
    • Epithelial Ovarian Cancer
    • Chula Vista, California
    • +2 more
    Nov 9, 2021

    Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)

    Terminated
    • Mantle Cell Lymphoma
    • Warszawa, Poland
    • +1 more
    Dec 23, 2021

    Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

    Recruiting
    • Relapse/Refractory Multiple Myeloma
    • DeepTag-GPRC5D Targeted CAR T-cells
    • Hangzhou, Zhejiang, China
      The first affiliated hospital of medical college of zhejiang uni
    Oct 10, 2023

    Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

    Completed
    • Fallopian Tube Cancer
    • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Apr 7, 2022

      Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

      Active, not recruiting
      • Recurrent B-Cell Non-Hodgkin Lymphoma
      • +7 more
      • Jacksonville, Florida
      • +11 more
      Jan 12, 2023

      Acute Leukaemia in Relapse Trial in Pierre Bénite (Supportive /palliative care intervention)

      Completed
      • Acute Leukaemia in Relapse
      • Supportive /palliative care intervention
      • Pierre Bénite, France
        Centre Hospitalier LYON SUD
      Feb 4, 2021

      DLBCL Trial in Rotterdam (R-DHAP, Brentuximab Vedotin)

      Recruiting
      • DLBCL
      • R-DHAP
      • Brentuximab Vedotin
      • Rotterdam, Netherlands
        NL-Rotterdam-ERASMUSMC
      Dec 9, 2020

      CBF and/or NPM1-mutated AML in First Molecular Relapse.

      Recruiting
      • Acute Myeloid Leukemia
      • No intervention
      • Angers, France
        Angers University Hospital
      Jun 14, 2021

      SEMA4C as a Relapse Biomarker in Breast Cancer

      Not yet recruiting
      • Breast Cancer
      • SEMA4C high value follow-up group
      • SEMA4C low value follow-up group
      • (no location specified)
      Oct 6, 2021